PURPOSE OF REVIEW: Atypical parkinsonian disorders (APDs) comprise a heterogenous group of disorders including multiple system atrophy (MSA), dementia with Lewy bodies (DLB), progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD). Based on literature published in 2010, we here review recent advances in the APD field. RECENT FINDINGS: Genome-wide association studies have provided robust evidence of increased disease risk conferred by synuclein and tau gene variants in MSA and PSP. Furthermore, advanced imaging tools have been established in the differential diagnosis and as surrogate markers of disease activity in patients with APDs. Finally, although therapeutic options are still disappointing, translational research into disease-modifying strategies has accelerated with the increasing availability of transgenic animal models, particularly for MSA. SUMMARY: Remarkable progress has been achieved in the field of APDs, and advances in the genetics, molecular biology and neuroimaging of these disorders will continue to facilitate intensified clinical trial activity.
PURPOSE OF REVIEW: Atypical parkinsonian disorders (APDs) comprise a heterogenous group of disorders including multiple system atrophy (MSA), dementia with Lewy bodies (DLB), progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD). Based on literature published in 2010, we here review recent advances in the APD field. RECENT FINDINGS: Genome-wide association studies have provided robust evidence of increased disease risk conferred by synuclein and tau gene variants in MSA and PSP. Furthermore, advanced imaging tools have been established in the differential diagnosis and as surrogate markers of disease activity in patients with APDs. Finally, although therapeutic options are still disappointing, translational research into disease-modifying strategies has accelerated with the increasing availability of transgenic animal models, particularly for MSA. SUMMARY: Remarkable progress has been achieved in the field of APDs, and advances in the genetics, molecular biology and neuroimaging of these disorders will continue to facilitate intensified clinical trial activity.
Authors: Helen Ling; Sean S O'Sullivan; Janice L Holton; Tamas Revesz; Luke A Massey; David R Williams; Dominic C Paviour; Andrew J Lees Journal: Brain Date: 2010-07 Impact factor: 13.501
Authors: Anna Hussl; Philipp Mahlknecht; Christoph Scherfler; Regina Esterhammer; Michael Schocke; Werner Poewe; Klaus Seppi Journal: Mov Disord Date: 2010-10-30 Impact factor: 10.338
Authors: Sean S O'Sullivan; Atbin Djamshidian; Zeshan Ahmed; Andrew H Evans; Andrew D Lawrence; Janice L Holton; Tamas Revesz; Andrew J Lees Journal: Mov Disord Date: 2010-04-15 Impact factor: 10.338
Authors: A Rojo; R S Pernaute; A Fontán; P G Ruíz; J Honnorat; T Lynch; S Chin; I Gonzalo; A Rábano; A Martínez; S Daniel; P Pramstaller; H Morris; N Wood; A Lees; C Tabernero; T Nyggard; A C Jackson; A Hanson; J G de Yébenes; P Pramsteller Journal: Brain Date: 1999-07 Impact factor: 13.501
Authors: I Litvan; Y Agid; D Calne; G Campbell; B Dubois; R C Duvoisin; C G Goetz; L I Golbe; J Grafman; J H Growdon; M Hallett; J Jankovic; N P Quinn; E Tolosa; D S Zee Journal: Neurology Date: 1996-07 Impact factor: 9.910
Authors: Axel Lipp; Paola Sandroni; J Eric Ahlskog; Robert D Fealey; Kurt Kimpinski; Valeria Iodice; Tonette L Gehrking; Stephen D Weigand; David M Sletten; Jade A Gehrking; Kim K Nickander; Wolfgang Singer; Demetrius M Maraganore; Sid Gilman; Gregor K Wenning; Clifford W Shults; Phillip A Low Journal: Arch Neurol Date: 2009-06
Authors: S Gilman; G K Wenning; P A Low; D J Brooks; C J Mathias; J Q Trojanowski; N W Wood; C Colosimo; A Dürr; C J Fowler; H Kaufmann; T Klockgether; A Lees; W Poewe; N Quinn; T Revesz; D Robertson; P Sandroni; K Seppi; M Vidailhet Journal: Neurology Date: 2008-08-26 Impact factor: 9.910
Authors: Alan M Pittman; Amanda J Myers; Jaime Duckworth; Leslie Bryden; Melissa Hanson; Patrick Abou-Sleiman; Nicholas W Wood; John Hardy; Andrew Lees; Rohan de Silva Journal: Hum Mol Genet Date: 2004-04-28 Impact factor: 6.150
Authors: Alfonso Fasano; Christian Geroin; Alfredo Berardelli; Bastiaan R Bloem; Alberto J Espay; Mark Hallett; Anthony E Lang; Michele Tinazzi Journal: Parkinsonism Relat Disord Date: 2018-05-08 Impact factor: 4.891
Authors: Ildefonso Rodríguez-Leyva; Ana Laura Calderón-Garcidueñas; María E Jiménez-Capdeville; Ana Arely Rentería-Palomo; Héctor Gerardo Hernandez-Rodriguez; Rodrigo Valdés-Rodríguez; Cornelia Fuentes-Ahumada; Bertha Torres-Álvarez; Julio Sepúlveda-Saavedra; Adolfo Soto-Domínguez; Martha E Santoyo; José Ildefonso Rodriguez-Moreno; Juan Pablo Castanedo-Cázares Journal: Ann Clin Transl Neurol Date: 2014-07-01 Impact factor: 4.511